Special Issue

Personalized Medicine in Organ Transplantation

Message from the Guest Editors

Transplantation has been nearly synonymous with personalized medicine, requiring specialized approaches to ABO blood typing, HLA classification, infectious disease treatment and prophylaxis, medication dosing, and surgical techniques. In the current era of precision medicine initiatives, the field of transplantation is ripe for innovation that is accelerating at a pace akin to Moore's Law. Practitioners in the field are constantly striving to provide the best possible care for patients in the context of shifting multi-level regulations and an urgency to meet the increasing demands for transplantable organs. Despite the progress, solutions to ongoing problems remain elusive, such as equitable allocation policies, pre-transplant risk assessment, optimal induction and maintenance immunosuppression regimens, and intelligent allograft monitoring protocols. This Special Issue of the *Journal* of Personalized Medicine aims to highlight some of the latest studies applying precision medicine to improve the care of people with end stage organ disease who are in need of or have undergone transplantation.

Guest Editors

Dr. Michael L. Kueht

Department of Surgery, Division of Multiorgan Transplant and Hepatobiliary Surgery, University of Texas Medical Branch, Galveston, TX, USA

Dr. Muhammad Mujtaba

Chief of Transplant, Medical Director of Kidney Transplantation, Division of Nephrology, University of Texas Medical Branch, Galveston, TX, USA

Deadline for manuscript submissions

closed (5 October 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/123738

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

